PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES

Abstract:

Prostate cancer (PC) is one of the most urgent problems in modern oncourology. Every year the world is recording more than 900 thousands new cases of prostate cancer. For this reason, the diagnosis and treatment of this disease has recently been given more attention, both abroad and in the Russian Federation. Despite improvements in diagnostic methods and implementation of programs for active detection of the disease in its early stages, the number of patients suffering from advanced forms of prostate cancer remains high. Currently, the main method of treatment in patients with metastatic prostate cancer remains the hormone therapy (HT). Patients with metastatic prostate cancer most frequently have localization of metastatic lesions in the lymph nodes and bones. Frequent localization of metastatic lesions in the bones is due to tumor cell tropism of prostate cancer to the bone. Metastatic bone disease, as well as long-term HT conducted in patients with metastatic prostate cancer, leads to irreversible disruption of bone remodeling, which may be accompanied by osteoporosis and fragility fractures. Bone metastases in patients with PC are the most common cause of complications and significantly impair the quality of life of patients. Therapy underlying the prevention of bone complications can be specific, aimed directly at the tumor tissue and non-specific, to strengthen bones and decrease its resorption processes. The article provides an overview of the literature covering the effectiveness of modern drugs, aimed at non-specific prevention of bone complications in patients with metastatic prostate cancer, such as bisphosphonates, and inhibitors of the ligand RANKL, as well as an overview of studies to assess the effectiveness of domestic analogue zolendronovoy acid preparation Resorba in the prevention of osteoporosis.

1. Zlokachestvennye novoobrazovaniya v Rossii v 2013 godu (zabolevaemost’ i smertnost’). Pod redaktsiei A. D. Kaprina, V. V. Starinskogo, G. V. Petrovoi. Moskva, 2015. (Russian).

2. Ilic D., O’Connor D., Green S., Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control. 2007 Apr; 18 (3): 279–285.

3. Bartsch G., Horninger W., Klocker H., et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001. Sep; 58 (3): 417–424.

4. Andriole G. L., Crawford E. D., Grubb R. L. 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360 (13): 1310–9.

5. Schröder F. H., Hugosson J., Roobol M. J., et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360 (13): 1320–8.

6. Garnick M. B. Prostate cancer: screening, diagnosis, and management. Ann Intern Med.1993; 118: 804–818.

7. Abrahamson Per-Anders. Revolutions in the management hormone-refractory prostate cancer. European Urology Supplements. 2003; 2: 1–2.

8. Kantoff P. W., Halabi S., Conaway M., et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999; 17: 2506–2513.

9. Berruti A., Tucci M., Mosca A. et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer. 2005; 93 (6): 633–638.

10. Harada M., Iida M., Yamaguchi M., et al. Analysis of bone metastasis of prostate adenocarcinoma in 137 autopsy cases. Adv Exp Mad Biol 1992;324: 173–182.

11. Clarke N. W., McClure J., George N. J. Osteoblast function and osteomalacia in metastatic prostate cancer. Eur Urol. 1993; 24: 286–290.

12. Clarke N. W., McClure J., George N. J. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991; 68: 74–80.

13. Garnero P., Buchs N., Zekri J., et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000; 82: 858–864.

14. Berruti A., Dogliotti L., Bitossi R., et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J Urol. 2000; 164: 1248–1253.

15. Kostenuik P. J., Singh G., Orr F. W. Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis. 1997; 15: 41–52.

16. Rajan R., Vanderslice R., Kapur S., et al. Epidermal growth factor (EGF) promotes chemomigration of a human prostate tumor cell line, and EGF immunoreactive proteins are present at sites of metastasis in the stroma of lymph nodes and medullar bone. Prostate. 1996; 28: 1–9.

17. Boyle W. J., Simonet W. S., Lancey D. L. Osteoclast differentiation and activation. Nature. 2003; 423: 337–342.

18. Holen I., Croucher P. I., Hamdy F. C., et al. Osteoprotegerin (OPG) is a survival factor for tumor prostate cancer cells. Cancer Res. 2002; 62: 1619–1623.

19. Wakchoure S., Swain T. M., Hentunen T. A., et al. Expression of macrophage inhibitory cytokine‑1 in prostate cancer bone metastases induces osteoclast activation and weight loss. Prostate. 2009; 69 (6): 652–661.

20. Reddi A. H., Roodman D., Freeman C., et al. Mechanisms of tumor metastases to the bone: challenges and opportunities. J of Bone and Mineral Research. 2003; 18: 190–194.

21. Mottet N., Bellmunt J., Briers E. et al. Guidelines on prostate cancer. EAU. 2015: 95–96.

22. Saad F., Gleason D. M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94 (19): 1458–68.

23. Aapro M., Abrahamsson P. A., Body J. J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol. 2008; 19 (3): 420–432.

24. Ofitsial’naya instruktsiya k preparatu Rezorba®. URL: http://medi.ru/doc/x1330.htm (data obrashcheniya 30.07.2015 g.) (Russian).

25. Daniell H. W., Dunn S. R., Ferguson D. W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000; 163 (1): 181–186.

26. Krupski T. L., Smith M. R., Chan Lee W., et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004; 101 (3): 541–549.

27. Fizazi K., Garducci M., Smith M., et al. Denosumab versus zolendronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. Lancet. 2011; 377 (9768): 813–822.

28. George R., Jeba J., Ramkumar G., et al. Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev 2008; 4: CD006716.